1. Home
  2. HNRG vs EVO Comparison

HNRG vs EVO Comparison

Compare HNRG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HNRG

Hallador Energy Company

HOLD

Current Price

$15.18

Market Cap

790.0M

Sector

Energy

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.16

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNRG
EVO
Founded
1949
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Coal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
790.0M
934.1M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
HNRG
EVO
Price
$15.18
$3.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$25.38
$7.00
AVG Volume (30 Days)
931.4K
74.4K
Earning Date
05-11-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
116.78
N/A
EPS
0.96
N/A
Revenue
$469,466,000.00
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
$12.12
$10.05
P/E Ratio
$16.41
N/A
Revenue Growth
16.09
N/A
52 Week Low
$13.60
$2.31
52 Week High
$24.70
$4.80

Technical Indicators

Market Signals
Indicator
HNRG
EVO
Relative Strength Index (RSI) 40.47 63.79
Support Level $15.02 $2.87
Resistance Level $21.07 $3.78
Average True Range (ATR) 0.85 0.09
MACD 0.06 0.10
Stochastic Oscillator 22.02 78.38

Price Performance

Historical Comparison
HNRG
EVO

About HNRG Hallador Energy Company

Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: